For Crohn’s Disease and Ulcerative Colitis, Company Reveals Results of New Study and Is Recruiting for Clinical Trial

For Crohn’s Disease and Ulcerative Colitis, Company Reveals Results of New Study and Is Recruiting for Clinical Trial
Immune Pharmaceuticals recently published new data on the impact of eotaxin-1 in ulcerative colitis (UC) and Crohn’s disease (CD). The article, “The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications,” was published in the journal Digestive Diseases and Sciences. Eotaxin-1 is a small protein that is involved in the recruitment of eosinophils

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *